Srigiridhar Kotamraju
9PUBLICATIONS
4CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (9)
Sort by Publication Date:
|Jan 29, 2026
Metadherin with Stromal-Immune Cues Drives CD36-Dependent Lipid Reprogramming and Metastasis in Triple-Negative Breast Cancer: Insights from a Hetero-Spheroid Model.Soumyadeep Poddar, Shashikanta Sahoo, Yogesh Chandra
|Dec 16, 2025
Doxorubicin Resistance Reprograms Triple-Negative Breast Cancer Cell Metabolism via the Fatty Acid β-Oxidation (FAO)-CD36 Regulatory Circuit: Relevance of Enhanced FAO on Tumor Cell Invasiveness.Sunita Kumari, Shashikanta Sahoo, Annatta Thomas
|Aug 13, 2024
SIRT1 promotes doxorubicin-induced breast cancer drug resistance and tumor angiogenesis via regulating GSH-mediated redox homeostasis.Shashikanta Sahoo, Sunita Kumari, Sriravali Pulipaka
|May 17, 2024
Mitochondria targeted esculetin administration improves insulin resistance and hyperglycemia-induced atherosclerosis in db/db mice.Gajalakshmi Singuru, Sriravali Pulipaka, Altab Shaikh
|Nov 15, 2023
Therapeutic efficacies of mitochondria-targeted esculetin and metformin in the improvement of age-associated atherosclerosis via regulating AMPK activation.Sriravali Pulipaka, Gajalakshmi Singuru, Shashikanta Sahoo
|Aug 26, 2022
DOT1L regulates MTDH-mediated angiogenesis in triple-negative breast cancer: intermediacy of NF-κB-HIF1α axis.Praveen Kumar Neeli, Shashikanta Sahoo, Santosh Karnewar
Pageof 2
